Kopran Limited · NSE:KOPRAN
Kopran — Q4 FY2023-24 Earnings Presentation
25 slides from Kopran's earnings presentation, 2024
Slide 1: Corporate Presentation Q4 & FY 2023-24
ONE DIRECTION, ENDLESS OPPORTUNITIES. CORPORATE PRESENTATION Q4 & FY 2023-24 KOPRAN LIMITED 1
Slide 2: Disclaimer
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 3: Q4 Performance
Q4 PERFORMANCE • Financial Highlights • API Highlights • Formulation Highlights
Slide 4: Consolidated Q4 FY 2023-24 Financial Highlights
Consolidated PARTICULARS Q4 FY 2023-24 Q4 FY 2022-23 Y-o-Y Q3 FY 2023-24 Q-o-Q Revenue from 18,608 15,800 17.8% 15,892 17.1% Operations Other Income 967 222 335.6% 243 298.1% EBITDA* 2,169 1,232 76.1% 2,358 -8.0% Finance Costs 259 224 - 224 - Depreciation 359 316 - 327 - Tax Expenses 656 219 - 471 -
Slide 5: Segment-wise Revenue Mix (Q-o-Q)
OPERATIONAL HIGHLIGHTS (Q-o-Q) SEGMENT-WISE REVENUE MIX Q4 FY 2023-24 (₹ LAKHS) Q3 FY 2023-24 (₹ LAKHS) Anti- Diabetic 63 Anti- Diabetic 370 47 86 17 Anti- Infective 498 Anti- Infective 280 927 Antibiotic-Urological Antibiotic-Urological Anti-Hypertensive Anti-Hypertensive 740 1,119 Neuromodulator N
Slide 6: Market-wise Revenue Mix (Q-o-Q)
OPERATIONAL HIGHLIGHTS (Q-o-Q) MARKET-WISE REVENUE MIX Q4 FY 2023-24 (₹ LAKHS) Q3 FY 2023-24 (₹ LAKHS) 4,558 3,149 Export Sales Export Sales Local Sales Local Sales 4,845 5,006 Total ₹ 9,402 Lakhs Total ₹ 8,155 Lakhs Note: Excluding solvent and scrap sales and includes API consumed for production of
Slide 7: Region-wise Sales Break-up (Q-o-Q)
OPERATIONAL HIGHLIGHTS (Q-o-Q) REGION-WISE SALES BREAK-UP Q4 FY 2023-24 (₹ LAKHS) Q3 FY 2023-24 (₹ LAKHS) Africa Africa 454 520 245 173 Canada Canada 579 677 1,637 Latem Latem 3,536 South Africa South Africa 53 Southeast Asia Southeast Asia UK UK 26 Middle East and North Middle East and North Africa
Slide 8: Product-wise Revenue Mix (Q-o-Q)
OPERATIONAL HIGHLIGHTS (Q-o-Q) PRODUCT-WISE REVENUE MIX Q4 FY 2023-24 (₹ LAKHS) Q3 FY 2023-24 (₹ LAKHS) 3,921 2,953 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 5,027 4,726 Total ₹ 8,948 Lakhs Total ₹ 7,679 Lakhs Note: Excluding Scrap Sales 8
Slide 9: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 10: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International Quality 50+ Formulations and Active Pharmaceutical Ingredients (APIs) globally Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and appr
Slide 11: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENTS Development, manufacturing and Anti-hypertensive sale of diverse APIs and Advanced Atenolol Macrolide Intermediates Cephalosporins - Non-Sterile Neuromodulator & Sterile One of the leaders in Atenolol Urological Macrolides One
Slide 12: Formulations Vertical
FORMULATIONS FORMULATIONS VERTICAL PRODUCT SEGMENTS Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs Catering 100% export markets of both Regulated and Non-Regulated markets Manufacturers of more than 100 dosages meet
Slide 13: Strategic Imperatives
STRATEGIC IMPERATIVES o Focus on R&D to develop niche, o Development of intermediates for high-value/high-volume APIs and APIs intermediates o Reducing dependence on China to o Capacity expansion move towards self sufficiency o Compliance with Global Regulatory COST o Optimising operational cost sta
Slide 14: Offering Best-in-Class Quality Through Strict Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards of manufacturing and quality at its all plants FORMULATIONS ACCREDITATIONS API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South Africa The
Slide 15: Operational Performance
OPERATIONAL PERFORMANCE
Slide 16: Segment-wise Revenue Mix (Y-o-Y)
OPERATIONAL HIGHLIGHTS (Y-o-Y) SEGMENT-WISE REVENUE MIX FY 2023-24 (₹ LAKHS) FY 2022-23 (₹ LAKHS) Anti- Diabetic Anti- Diabetic 39 107 939 181 319 213 Anti- Infective 637 Anti- Infective 3,245 1,244 Antibiotic-Urological Antibiotic-Urological Anti-Hypertensive 5,847 Anti-Hypertensive 60 162 Neuromod
Slide 17: Market-wise Revenue Mix (Y-o-Y)
OPERATIONAL HIGHLIGHTS (Y-o-Y) MARKET-WISE REVENUE MIX FY 2023-24 (₹ LAKHS) FY 2022-23 (₹ LAKHS) 14,324 15,228 Export Sales Export Sales Local Sales Local Sales 18,964 14,967 Total ₹ 33,288 Lakhs Total ₹ 30,195 Lakhs Note: Excluding solvent and scrap sales and includes API consumed for production of
Slide 18: Region-wise Sales Break-up (Y-o-Y)
OPERATIONAL HIGHLIGHTS (Y-o-Y) REGION-WISE SALES BREAK-UP FY 2023-24 (₹ LAKHS) FY 2022-23 (₹ LAKHS) Africa Africa 1,764 1,865 508 242 Canada Canada 1,848 2,496 Latem 8,873 Latem 7,428 South Africa South Africa Southeast Asia Southeast Asia UK UK 68 73 Middle East and North Middle East and North Afri
Slide 19: Product-wise Revenue Mix (Y-o-Y)
OPERATIONAL HIGHLIGHTS (Y-o-Y) PRODUCT-WISE REVENUE MIX Y-oY FY 2023-24 (₹ LAKHS) FY 2022-23 (₹ LAKHS) 10,273 11,955 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 15,901 14,816 Total ₹ 27,856 Lakhs Total ₹ 25,089 Lakhs Note: Excluding Scrap Sales 19
Slide 20: Financial Performance
FINANCIAL PERFORMANCE
Slide 21: Snapshot
SNAPSHOT 62,920 50,980 55,405 48,813 36,013 SALES/OTHER INCOME (₹ LAKHS) 8,178 8,739 2019-20 2020-21 2021-22 2022-23 2023-24 7,441 4,696 5,180 EBITDA * (₹ LAKHS) 891 859 2019-20 2020-21 2021-22 2022-23 2023-24 624 608 512 FINANCE COSTS (₹ LAKHS) 2019-20 2020-21 2021-22 2022-23 2023-24 6,161 6,103 5,
Slide 22: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR RoE (%) RoCE (%) 25.3 28.3 22.4 14.5 20.1 14.1 8.3 11.8 11 EBITDA & EBITDA Margin 6.3 Net Debt/Equity (₹ Lakhs, %) (X) 2019-20 2020-21 2021-22 2022-23 2023-24 16.6 18.3 Return on Networth/Equity 13.1 Return on Capital Employed 11.8 8,739 9.0 8,178 0.39 7,441 5
Slide 23: Five-Year Financial Summary
PARTICULARS FY 2023-24 FY 2022-23 Y-o-Y % FY 2021-22 FY 2020-21 FY 2019-20 Revenue from Operations 61,459 55,098 11.5 47,752 49,181 35,949 Equity Share Capital 4,821 4,821 - 4,821 4,325 4,324 Other Equity 44,303 39,104 - 37,796 20,177 14,643 Net Worth 49,125 43,925 11.8 42,617 24,503 18,968 Fixed As
Slide 24: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MRS. MAMTA BIYANI MR. NARAYAN ATAL EXECUTIVE VICE CHAIRMAN DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR DR. SIDDHAN SUBRAMANIAN DR. SUNITA BANERJI MR. SUSHEEL SOMANI MR. VARUN SURENDRA SOMANI INDEPENDENT DIRECTOR INDEPENDENT DIR
Slide 25: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P